Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Enzalutamide
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Bipolar Androgen Therapy
100%
Multi-cohort Study
100%
Rechallenge
20%
Retreatment
13%
Testosterone
13%
Adverse Events
13%
Prostate-specific Antigen
13%
Anti-androgen Therapy
13%
Myocardial Infarction
6%
Prostate Cancer
6%
Castration-resistant Prostate Cancer
6%
Single Center
6%
Hypertension
6%
National Cancer Institute
6%
Tumor Response
6%
Serum Testosterone
6%
Pulmonary Embolism
6%
Abiraterone
6%
Optimal Strategy
6%
Agonist Treatment
6%
National Institutes of Health
6%
Bone Lesions
6%
Gallstones
6%
Patient-completed
6%
Clinical Role
6%
Luteinizing Hormone
6%
Antigen Concentration
6%
Treatment-related Mortality
6%
Intention-to-treat Analysis
6%
Androgen Therapy
6%
Therapeutic Implications
6%
Treatment Discontinuation
6%
Urinary Obstruction
6%
Impending Fracture
6%
Rapid Cycling
6%
High-risk Lesions
6%
Safe Therapy
6%
Low Testosterone
6%
Urinary Sepsis
6%
Tumor Flare
6%
Co-sensitization
6%
One Dose
6%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
6%
Co-primary Endpoints
6%
Second-line Hormonal Therapy
6%
Visceral Disease
6%
Medicine and Dentistry
Castration Resistant Prostate Cancer
100%
Androgen Therapy
100%
Enzalutamide
100%
Adverse Event
12%
Retreatment
12%
Prostate Specific Antigen
12%
Antiandrogen Therapy
12%
Testosterone
12%
Malignant Neoplasm
6%
Oncology
6%
Prostate Cancer
6%
Sepsis
6%
Myocardial Infarction
6%
Pulmonary Embolism
6%
Hormone Therapy
6%
Intention-to-Treat Analysis
6%
Gallstone
6%
Gonadorelin Agonist
6%
Bone Lesion
6%
Urinary Tract Obstruction
6%
Abiraterone
6%
Tumor
6%
Tumor Flare
6%
Testosterone Cipionate
6%
Diseases
6%
Oral
6%
Hypertension
6%
Pharmacology, Toxicology and Pharmaceutical Science
Enzalutamide
100%
Castration Resistant Prostate Cancer
100%
Androgen
100%
Antiandrogen
12%
Prostate Specific Antigen
12%
Adverse Event
12%
Testosterone
12%
Hormone Cancer Therapy
6%
Malignant Neoplasm
6%
Prostate Cancer
6%
Heart Infarction
6%
Abiraterone
6%
Lung Embolism
6%
Gonadorelin Agonist
6%
Urinary Tract Obstruction
6%
Bone Lesion
6%
Testosterone Cipionate
6%
Tumor Flare
6%
Sepsis
6%
Gallstone
6%
Diseases
6%
Hypertension
6%